NO324991B1 - GnRH antagonistpeptid samt farmasoytisk preparat inneholdende det samme. - Google Patents

GnRH antagonistpeptid samt farmasoytisk preparat inneholdende det samme. Download PDF

Info

Publication number: NO324991B1
Authority: NO; Norway
Prior art keywords: 4aph; ala; hor; peptide; 4amf
Prior art date: 1997-04-11

Application number

NO19994906A

Other languages

English (en)

Norwegian (no)

Other versions

NO994906L (no

NO994906D0 (no

Inventor

Graeme Semple

Guangcheng Jiang

Original Assignee

Ferring Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-11

Filing date

1999-10-08

Publication date

2008-01-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25273352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO324991(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-10-08 Application filed by Ferring Bv filed Critical Ferring Bv

1999-10-08 Publication of NO994906D0 publication Critical patent/NO994906D0/no

1999-12-13 Publication of NO994906L publication Critical patent/NO994906L/no

2008-01-14 Publication of NO324991B1 publication Critical patent/NO324991B1/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 173
229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 title claims description 53
239000002474 gonadorelin antagonist Substances 0.000 title claims description 29
239000000825 pharmaceutical preparation Substances 0.000 title claims description 6
-1 D-Ala-ol Chemical compound 0.000 claims description 42
230000028327 secretion Effects 0.000 claims description 32
150000003839 salts Chemical class 0.000 claims description 19
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 18
BKMMTJMQCTUHRP-VKHMYHEASA-N (S)-2-aminopropan-1-ol Chemical compound C[C@H](N)CO BKMMTJMQCTUHRP-VKHMYHEASA-N 0.000 claims description 15
HQMLIDZJXVVKCW-UWTATZPHSA-N (2r)-2-aminopropanamide Chemical compound C[C@@H](N)C(N)=O HQMLIDZJXVVKCW-UWTATZPHSA-N 0.000 claims description 13
DFZVZEMNPGABKO-SSDOTTSWSA-N (2r)-2-amino-3-pyridin-3-ylpropanoic acid Chemical compound OC(=O)[C@H](N)CC1=CC=CN=C1 DFZVZEMNPGABKO-SSDOTTSWSA-N 0.000 claims description 12
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 9
241000124008 Mammalia Species 0.000 claims description 9
102000006771 Gonadotropins Human genes 0.000 claims description 8
108010086677 Gonadotropins Proteins 0.000 claims description 8
239000002622 gonadotropin Substances 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 7
229940094892 gonadotropins Drugs 0.000 claims description 7
BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
125000002252 acyl group Chemical group 0.000 claims description 5
KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 claims description 4
HQMLIDZJXVVKCW-REOHCLBHSA-N L-alaninamide Chemical compound C[C@H](N)C(N)=O HQMLIDZJXVVKCW-REOHCLBHSA-N 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
230000002401 inhibitory effect Effects 0.000 claims description 4
231100000252 nontoxic Toxicity 0.000 claims description 4
230000003000 nontoxic effect Effects 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
125000004432 carbon atom Chemical group C* 0.000 claims description 3
239000000203 mixture Substances 0.000 claims description 3
238000004458 analytical method Methods 0.000 description 51
102000009151 Luteinizing Hormone Human genes 0.000 description 50
108010073521 Luteinizing Hormone Proteins 0.000 description 50
229940040129 luteinizing hormone Drugs 0.000 description 50
230000015572 biosynthetic process Effects 0.000 description 49
238000003786 synthesis reaction Methods 0.000 description 46
230000001629 suppression Effects 0.000 description 40
238000000746 purification Methods 0.000 description 39
229920005989 resin Polymers 0.000 description 38
239000011347 resin Substances 0.000 description 38
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
238000004007 reversed phase HPLC Methods 0.000 description 34
125000006239 protecting group Chemical group 0.000 description 33
238000001727 in vivo Methods 0.000 description 29
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 26
238000010511 deprotection reaction Methods 0.000 description 26
238000012360 testing method Methods 0.000 description 26
241000700159 Rattus Species 0.000 description 25
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 24
238000003776 cleavage reaction Methods 0.000 description 21
239000000543 intermediate Substances 0.000 description 21
230000007017 scission Effects 0.000 description 21
238000006243 chemical reaction Methods 0.000 description 19
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 16
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 16
102000004196 processed proteins & peptides Human genes 0.000 description 16
230000000975 bioactive effect Effects 0.000 description 15
150000001875 compounds Chemical class 0.000 description 15
MGOLNIXAPIAKFM-UHFFFAOYSA-N 2-isocyanato-2-methylpropane Chemical compound CC(C)(C)N=C=O MGOLNIXAPIAKFM-UHFFFAOYSA-N 0.000 description 12
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 12
238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 11
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 11
UFIVEPVSAGBUSI-REOHCLBHSA-N (S)-dihydroorotic acid Chemical compound OC(=O)[C@@H]1CC(=O)NC(=O)N1 UFIVEPVSAGBUSI-REOHCLBHSA-N 0.000 description 10
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 10
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
238000000034 method Methods 0.000 description 10
239000000243 solution Substances 0.000 description 10
UFIVEPVSAGBUSI-UHFFFAOYSA-N dihydroorotic acid Chemical compound OC(=O)C1CC(=O)NC(=O)N1 UFIVEPVSAGBUSI-UHFFFAOYSA-N 0.000 description 9
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 8
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 8
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 8
239000002253 acid Substances 0.000 description 8
235000001014 amino acid Nutrition 0.000 description 8
150000001413 amino acids Chemical class 0.000 description 8
125000003277 amino group Chemical group 0.000 description 8
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 8
239000000872 buffer Substances 0.000 description 7
108700008462 cetrorelix Proteins 0.000 description 7
230000000694 effects Effects 0.000 description 7
229940088597 hormone Drugs 0.000 description 7
239000005556 hormone Substances 0.000 description 7
238000011282 treatment Methods 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
BKMMTJMQCTUHRP-GSVOUGTGSA-N (2r)-2-aminopropan-1-ol Chemical group C[C@@H](N)CO BKMMTJMQCTUHRP-GSVOUGTGSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 6
229960003230 cetrorelix Drugs 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
150000003431 steroids Chemical class 0.000 description 6
239000000126 substance Substances 0.000 description 6
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
239000005557 antagonist Substances 0.000 description 5
230000037396 body weight Effects 0.000 description 5
230000008878 coupling Effects 0.000 description 5
238000010168 coupling process Methods 0.000 description 5
238000005859 coupling reaction Methods 0.000 description 5
UNXNGGMLCSMSLH-UHFFFAOYSA-N dihydrogen phosphate;triethylazanium Chemical compound OP(O)(O)=O.CCN(CC)CC UNXNGGMLCSMSLH-UHFFFAOYSA-N 0.000 description 5
BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 5
238000001879 gelation Methods 0.000 description 5
HAMGRBXTJNITHG-UHFFFAOYSA-N methyl isocyanate Chemical compound CN=C=O HAMGRBXTJNITHG-UHFFFAOYSA-N 0.000 description 5
238000006467 substitution reaction Methods 0.000 description 5
229960003604 testosterone Drugs 0.000 description 5
238000005406 washing Methods 0.000 description 5
KZKRPYCBSZIQKN-REOHCLBHSA-N (4s)-2-oxoimidazolidine-4-carboxylic acid Chemical compound OC(=O)[C@@H]1CNC(=O)N1 KZKRPYCBSZIQKN-REOHCLBHSA-N 0.000 description 4
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 4
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 4
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
229940028334 follicle stimulating hormone Drugs 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
230000007774 longterm Effects 0.000 description 4
230000016087 ovulation Effects 0.000 description 4
ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
230000021736 acetylation Effects 0.000 description 3
238000006640 acetylation reaction Methods 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
125000000539 amino acid group Chemical class 0.000 description 3
230000003385 bacteriostatic effect Effects 0.000 description 3
239000003433 contraceptive agent Substances 0.000 description 3
230000001747 exhibiting effect Effects 0.000 description 3
230000035558 fertility Effects 0.000 description 3
239000012634 fragment Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000002710 gonadal effect Effects 0.000 description 3
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
239000007929 subcutaneous injection Substances 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 description 2
GNVNKFUEUXUWDV-VIFPVBQESA-N (2s)-2-amino-3-[4-(aminomethyl)phenyl]propanoic acid Chemical compound NCC1=CC=C(C[C@H](N)C(O)=O)C=C1 GNVNKFUEUXUWDV-VIFPVBQESA-N 0.000 description 2
HBAHZZVIEFRTEY-UHFFFAOYSA-N 2-heptylcyclohex-2-en-1-one Chemical compound CCCCCCCC1=CCCCC1=O HBAHZZVIEFRTEY-UHFFFAOYSA-N 0.000 description 2
CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 2
125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 2
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical class OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
229920001367 Merrifield resin Polymers 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
101100109397 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arg-8 gene Proteins 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
235000004279 alanine Nutrition 0.000 description 2
125000003275 alpha amino acid group Chemical group 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
108010070670 antarelix Proteins 0.000 description 2
230000003517 anti-gonadal effect Effects 0.000 description 2
239000012062 aqueous buffer Substances 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
238000005515 capillary zone electrophoresis Methods 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229940124558 contraceptive agent Drugs 0.000 description 2
230000007423 decrease Effects 0.000 description 2
MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
101150089730 gly-10 gene Proteins 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
229960001340 histamine Drugs 0.000 description 2
239000008240 homogeneous mixture Substances 0.000 description 2
230000003054 hormonal effect Effects 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
210000003016 hypothalamus Anatomy 0.000 description 2
239000012535 impurity Substances 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000012948 isocyanate Substances 0.000 description 2
150000002513 isocyanates Chemical class 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 2
230000001817 pituitary effect Effects 0.000 description 2
208000006155 precocious puberty Diseases 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
108010004034 stable plasma protein solution Proteins 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
DMBKPDOAQVGTST-GFCCVEGCSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylmethoxypropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)COCC1=CC=CC=C1 DMBKPDOAQVGTST-GFCCVEGCSA-N 0.000 description 1
AWHLZPUCOBVQKQ-VIFPVBQESA-N (2s)-2-amino-4-(4-aminophenyl)butanoic acid Chemical compound OC(=O)[C@@H](N)CCC1=CC=C(N)C=C1 AWHLZPUCOBVQKQ-VIFPVBQESA-N 0.000 description 1
ZODMYTRQCNEOFM-QMMMGPOBSA-N (2s)-6-amino-2-(propan-2-ylamino)hexanoic acid Chemical compound CC(C)N[C@H](C(O)=O)CCCCN ZODMYTRQCNEOFM-QMMMGPOBSA-N 0.000 description 1
HYLARTCUZHPNQK-JTQLQIEISA-N (2s)-6-amino-2-(pyridine-3-carbonylamino)hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)C1=CC=CN=C1 HYLARTCUZHPNQK-JTQLQIEISA-N 0.000 description 1
UKRWCEJTOPSTEC-RDTXWAMCSA-N (6ar,9r)-4-acetyl-n-ethyl-7-methyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)NCC)C2)=C3C2=CN(C(C)=O)C3=C1 UKRWCEJTOPSTEC-RDTXWAMCSA-N 0.000 description 1
UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
MAEDLSNGVQYGPK-UHFFFAOYSA-N 2,2-diaminoacetic acid Chemical compound NC(N)C(O)=O MAEDLSNGVQYGPK-UHFFFAOYSA-N 0.000 description 1
SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical compound N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 1
ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 description 1
VLJQDHDVZJXNQL-UHFFFAOYSA-N 4-methyl-n-(oxomethylidene)benzenesulfonamide Chemical compound CC1=CC=C(S(=O)(=O)N=C=O)C=C1 VLJQDHDVZJXNQL-UHFFFAOYSA-N 0.000 description 1
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical class NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical class NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
125000005076 adamantyloxycarbonyl group Chemical group C12(CC3CC(CC(C1)C3)C2)OC(=O)* 0.000 description 1
125000003158 alcohol group Chemical group 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000002052 anaphylactic effect Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
230000002513 anti-ovulatory effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
206010003883 azoospermia Diseases 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
239000012459 cleaning agent Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
210000002149 gonad Anatomy 0.000 description 1
230000001456 gonadotroph Effects 0.000 description 1
238000006698 hydrazinolysis reaction Methods 0.000 description 1
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
NIZHERJWXFHGGU-UHFFFAOYSA-N isocyanato(trimethyl)silane Chemical compound C[Si](C)(C)N=C=O NIZHERJWXFHGGU-UHFFFAOYSA-N 0.000 description 1
YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 1
125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
UBLQIESZTDNNAO-UHFFFAOYSA-N n,n-diethylethanamine;phosphoric acid Chemical compound [O-]P([O-])([O-])=O.CC[NH+](CC)CC.CC[NH+](CC)CC.CC[NH+](CC)CC UBLQIESZTDNNAO-UHFFFAOYSA-N 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
238000006303 photolysis reaction Methods 0.000 description 1
230000015843 photosynthesis, light reaction Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000026234 pro-estrus Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
230000021595 spermatogenesis Effects 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
239000003270 steroid hormone Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
230000002483 superagonistic effect Effects 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
238000007079 thiolysis reaction Methods 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical group C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/11—Gonadotropin; related peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Endocrinology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Reproductive Health (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Immunology (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

NO19994906A 1997-04-11 1999-10-08 GnRH antagonistpeptid samt farmasoytisk preparat inneholdende det samme. NO324991B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/837,042 US5925730A (en)	1997-04-11	1997-04-11	GnRH antagonists
PCT/US1998/007438 WO1998046634A1 (en)	1997-04-11	1998-04-13	GnRH ANTAGONISTS BEING MODIFIED IN POSITIONS 5 AND 6

Publications (3)

Publication Number	Publication Date
NO994906D0 NO994906D0 (no)	1999-10-08
NO994906L NO994906L (no)	1999-12-13
NO324991B1 true NO324991B1 (no)	2008-01-14

Family

ID=25273352

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO19994906A NO324991B1 (no)	1997-04-11	1999-10-08	GnRH antagonistpeptid samt farmasoytisk preparat inneholdende det samme.
NO2009016C NO2009016I2 (no)	1997-04-11	2009-07-23	D-alaninamid, N-acetyl-3(2-naftalenyl)-D-alanyl-4-klor-D-fenylalanyl-3(3-pyridinyl)-D-alanyl-L-seryl-4[[[(4S)-heksahydro-2,6-diokso-4-pyrimidinyl]karbonyl]amino]-L-fenylalanyl-4[(aminokarbonyl)amino]-D-fenvlalanvl-L-leucvl-N6(1-metvletvl-L-1vsvl-L-nrolvl-

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2009016C NO2009016I2 (no)	1997-04-11	2009-07-23	D-alaninamid, N-acetyl-3(2-naftalenyl)-D-alanyl-4-klor-D-fenylalanyl-3(3-pyridinyl)-D-alanyl-L-seryl-4[[[(4S)-heksahydro-2,6-diokso-4-pyrimidinyl]karbonyl]amino]-L-fenylalanyl-4[(aminokarbonyl)amino]-D-fenvlalanvl-L-leucvl-N6(1-metvletvl-L-1vsvl-L-nrolvl-

Country Status (37)

Country	Link
US (2)	US5925730A (zh)
EP (1)	EP1003774B1 (zh)
JP (2)	JP4249806B2 (zh)
KR (1)	KR100519421B1 (zh)
CN (1)	CN1230442C (zh)
AR (1)	AR011217A1 (zh)
AT (1)	ATE319736T1 (zh)
AU (1)	AU728642B2 (zh)
BR (1)	BR9808523B1 (zh)
CA (1)	CA2286190C (zh)
CY (2)	CY1108063T1 (zh)
CZ (1)	CZ299097B6 (zh)
DE (2)	DE69833751T2 (zh)
DK (1)	DK1003774T3 (zh)
EE (1)	EE03974B1 (zh)
ES (1)	ES2260833T3 (zh)
FR (1)	FR09C0028I2 (zh)
HK (1)	HK1025104A1 (zh)
HR (1)	HRP980197B1 (zh)
HU (1)	HU224836B1 (zh)
IL (1)	IL132303A0 (zh)
LU (1)	LU91585I2 (zh)
MY (1)	MY114811A (zh)
NL (1)	NL300395I2 (zh)
NO (2)	NO324991B1 (zh)
NZ (1)	NZ500142A (zh)
PL (1)	PL194509B1 (zh)
PT (1)	PT1003774E (zh)
RU (1)	RU2199549C2 (zh)
SI (1)	SI1003774T1 (zh)
SK (1)	SK285381B6 (zh)
TR (1)	TR199902956T2 (zh)
TW (1)	TW505658B (zh)
UA (1)	UA58547C2 (zh)
UY (1)	UY24958A1 (zh)
WO (1)	WO1998046634A1 (zh)
ZA (1)	ZA983062B (zh)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6828415B2 (en) *	1993-02-19	2004-12-07	Zentaris Gmbh	Oligopeptide lyophilisate, their preparation and use
US5925730A (en) *	1997-04-11	1999-07-20	Ferring Bv	GnRH antagonists
US5977302A (en) *	1997-11-20	1999-11-02	Ortho-Mcneil Pharmaceutical, Inc.	Liquid phase process for the preparation of GnRH peptides
US8119159B2 (en) *	1999-02-22	2012-02-21	Merrion Research Iii Limited	Solid oral dosage form containing an enhancer
US7658938B2 (en) *	1999-02-22	2010-02-09	Merrion Reasearch III Limited	Solid oral dosage form containing an enhancer
US20070148228A1 (en) *	1999-02-22	2007-06-28	Merrion Research I Limited	Solid oral dosage form containing an enhancer
GB0117057D0 (en) *	2001-07-12	2001-09-05	Ferring Bv	Pharmaceutical composition
IL147138A0 (en) *	2001-12-17	2002-08-14	Yeda Res & Dev	Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
EP2322197A2 (en)	2003-11-10	2011-05-18	Reprise Biopharmaceutics, LLC	Pharmaceutical compositions including low dosages of desmopressin
DE20321887U1 (de)	2003-11-10	2012-01-20	Allergan, Inc.	Arzneimittel umfassend niedrige Dosierungen von Desmopressin
CN101037472B (zh) *	2006-03-14	2013-03-27	中国人民解放军军事医学科学院毒物药物研究所	具有低组胺释放作用的促黄体生成素释放激素拮抗剂
US7704977B2 (en) *	2006-04-07	2010-04-27	Merrion Research Iii Limited	Solid oral dosage form containing an enhancer
TWI539959B (zh)	2008-02-11	2016-07-01	菲瑞茵國際中心股份有限公司	治療轉移階段攝護腺癌的方法
TW200950799A (en) *	2008-05-07	2009-12-16	Merrion Res Iii Ltd	Compositions of GnRH related compounds and processes of preparation
US20100215743A1 (en) *	2009-02-25	2010-08-26	Leonard Thomas W	Composition and drug delivery of bisphosphonates
KR101621725B1 (ko) *	2009-04-24	2016-05-17	폴리펩타이드 라보라토리즈 에이/에스	데가렐릭스의 제조 방법
CN105663059A (zh) *	2009-05-01	2016-06-15	辉凌公司	用于治疗前列腺癌的组合物
TW201043221A (en) *	2009-05-06	2010-12-16	Ferring Int Ct Sa	Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) *	2009-07-06	2011-02-17	Ferring International Center S.A.	Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en)	2009-11-25	2011-06-03	Novetide, Ltd.	Process for production of degarelix
US20110182985A1 (en) *	2010-01-28	2011-07-28	Coughlan David C	Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) *	2010-03-26	2015-07-28	Merrion Research Iii Limited	Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
US9260480B2 (en)	2010-10-27	2016-02-16	Ferring B.V.	Process for the manufacture of Degarelix and its intermediates
EP2447276A1 (en) *	2010-10-27	2012-05-02	Ferring B.V.	Process for the manufacture of Degarelix and its intermediates
EP2654772B1 (en)	2010-12-22	2018-09-26	The Salk Institute for Biological Studies	Cyclic crf antagonist peptides
KR20140026354A (ko)	2011-01-07	2014-03-05	메리온 리서치 Ⅲ 리미티드	경구 투여용 철의 제약 조성물
JO3755B1 (ar)	2011-01-26	2021-01-31	Ferring Bv	تركيبات تستوستيرون
WO2013104745A1 (en)	2012-01-13	2013-07-18	Ferring Bv	Pharmaceutical composition
SG11201407679PA (en)	2012-06-01	2014-12-30	Ferring Bv	Manufacture of degarelix
ES2975708T3 (es)	2015-01-29	2024-07-12	Novo Nordisk As	Comprimidos que comprenden agonista del GLP-1 y recubrimiento entérico
CN108779150B (zh) *	2015-12-17	2022-03-29	费森尤斯卡比依普莎姆责任有限公司	地加瑞克的制备方法及其中间体
CN107778355B (zh) *	2016-08-25	2021-04-20	成都圣诺生物制药有限公司	一种合成西曲瑞克的方法
WO2019110688A1 (en)	2017-12-05	2019-06-13	Ferring B.V.	A composition comprising degarelix for use in the treatment of breast cancer
US20220267347A1 (en)	2019-07-29	2022-08-25	Sunshine Lake Pharma Co., Ltd.	Substituted pyrimidinedione compounds and uses thereof
US11332495B2 (en)	2019-09-21	2022-05-17	RK Pharma Solutions LLC	Process for the preparation of Degarelix acetate and Degarelix acetate-mannitol premix
CN114456236A (zh) *	2020-11-09	2022-05-10	深圳市健翔生物制药有限公司	一种地加瑞克乙酰化杂质的制备方法
US20250000864A1 (en)	2021-11-01	2025-01-02	Shandong Luye Pharmaceutical Co., Ltd.	Gonadotropin-releasing hormone antagonist, and preparation method therefor and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4547370A (en) *	1983-11-29	1985-10-15	The Salk Institute For Biological Studies	GnRH Antagonists
US4508921A (en) *	1984-06-28	1985-04-02	Merck & Co., Inc.	Process for preparation of alpha-alkyl amino acids
US4866160A (en) *	1985-04-09	1989-09-12	The Administrators Of The Tulane Educational Fund	Therapeutic decapeptides
US5073624A (en) *	1985-04-09	1991-12-17	Administrators Of The Tulane Educational Fund	Therapeutic decapeptides
US4800191A (en) *	1987-07-17	1989-01-24	Schally Andrew Victor	LHRH antagonists
US4935491A (en) *	1987-08-24	1990-06-19	Board Of Regents, The University Of Texas System	Effective antagonists of the luteinizing hormone releasing hormone which release negligible histamine
US5171835A (en) *	1988-10-21	1992-12-15	The Administrators Of The Tulane Educational Fund	LHRH antagonists
US5296468A (en) *	1989-10-30	1994-03-22	The Salk Institute For Biological Studies	GnRH analogs
DE593491T1 (de) *	1991-04-25	1994-11-17	Romano S.-Cergue Deghenghi	LHRH-Antagonisten.
EP0683792B1 (en) *	1992-12-18	2001-09-26	Abbott Laboratories	Lhrh antagonists having modified aminoacyl residues at postions 5 and 6
IL108509A0 (en) *	1993-02-22	1994-05-30	Salk Inst For Biological Studi	GnRH antagonist peptides
US5506207A (en) *	1994-03-18	1996-04-09	The Salk Institute For Biological Studies	GNRH antagonists XIII
US5843901A (en) *	1995-06-07	1998-12-01	Advanced Research & Technology Institute	LHRH antagonist peptides
US5925730A (en) *	1997-04-11	1999-07-20	Ferring Bv	GnRH antagonists

1997
- 1997-04-11 US US08/837,042 patent/US5925730A/en not_active Expired - Lifetime
1998
- 1998-04-08 AR ARP980101612A patent/AR011217A1/es active IP Right Grant
- 1998-04-09 MY MYPI98001566A patent/MY114811A/en unknown
- 1998-04-09 HR HR980197A patent/HRP980197B1/xx not_active IP Right Cessation
- 1998-04-09 ZA ZA983062A patent/ZA983062B/xx unknown
- 1998-04-13 ES ES98915539T patent/ES2260833T3/es not_active Expired - Lifetime
- 1998-04-13 UY UY24958A patent/UY24958A1/es not_active Application Discontinuation
- 1998-04-13 WO PCT/US1998/007438 patent/WO1998046634A1/en active IP Right Grant
- 1998-04-13 EE EEP199900479A patent/EE03974B1/xx active Protection Beyond IP Right Term
- 1998-04-13 IL IL13230398A patent/IL132303A0/xx active Protection Beyond IP Right Term
- 1998-04-13 NZ NZ500142A patent/NZ500142A/en not_active IP Right Cessation
- 1998-04-13 KR KR10-1999-7009315A patent/KR100519421B1/ko not_active IP Right Cessation
- 1998-04-13 BR BRPI9808523-9A patent/BR9808523B1/pt not_active IP Right Cessation
- 1998-04-13 CN CNB988060337A patent/CN1230442C/zh not_active Expired - Lifetime
- 1998-04-13 US US09/402,698 patent/US6214798B1/en not_active Expired - Lifetime
- 1998-04-13 PL PL98336213A patent/PL194509B1/pl unknown
- 1998-04-13 SI SI9830832T patent/SI1003774T1/sl unknown
- 1998-04-13 DE DE69833751T patent/DE69833751T2/de not_active Expired - Lifetime
- 1998-04-13 DK DK98915539T patent/DK1003774T3/da active
- 1998-04-13 AT AT98915539T patent/ATE319736T1/de active
- 1998-04-13 PT PT98915539T patent/PT1003774E/pt unknown
- 1998-04-13 AU AU69698/98A patent/AU728642B2/en not_active Expired
- 1998-04-13 SK SK1396-99A patent/SK285381B6/sk not_active IP Right Cessation
- 1998-04-13 RU RU99123619/04A patent/RU2199549C2/ru not_active IP Right Cessation
- 1998-04-13 CZ CZ0358699A patent/CZ299097B6/cs not_active IP Right Cessation
- 1998-04-13 HU HU0002704A patent/HU224836B1/hu active Protection Beyond IP Right Term
- 1998-04-13 UA UA99105726A patent/UA58547C2/uk unknown
- 1998-04-13 EP EP98915539A patent/EP1003774B1/en not_active Expired - Lifetime
- 1998-04-13 TR TR1999/02956T patent/TR199902956T2/xx unknown
- 1998-04-13 JP JP54418398A patent/JP4249806B2/ja not_active Expired - Lifetime
- 1998-04-13 CA CA002286190A patent/CA2286190C/en not_active Expired - Lifetime
- 1998-04-13 DE DE200912000033 patent/DE122009000033I2/de active Active
- 1998-05-06 TW TW087106980A patent/TW505658B/zh not_active IP Right Cessation
1999
- 1999-10-08 NO NO19994906A patent/NO324991B1/no not_active IP Right Cessation
2000
- 2000-07-13 HK HK00104333A patent/HK1025104A1/xx not_active IP Right Cessation
2004
- 2004-11-04 JP JP2004320615A patent/JP3645255B1/ja not_active Expired - Lifetime
2006
- 2006-06-07 CY CY20061100747T patent/CY1108063T1/el unknown
2009
- 2009-07-03 CY CY2009008C patent/CY2009008I1/el unknown
- 2009-07-15 FR FR09C0028C patent/FR09C0028I2/fr active Active
- 2009-07-17 LU LU91585C patent/LU91585I2/fr unknown
- 2009-07-17 NL NL300395C patent/NL300395I2/nl unknown
- 2009-07-23 NO NO2009016C patent/NO2009016I2/no unknown

Also Published As

Publication number	Publication date
FR09C0028I2 (fr)	2010-06-11
DK1003774T3 (da)	2006-07-03
MY114811A (en)	2003-01-31
IL132303A0 (en)	2001-03-19
BR9808523A (pt)	2000-05-23
EP1003774B1 (en)	2006-03-08
BR9808523B1 (pt)	2010-02-09
NO2009016I1 (no)	2009-08-10
FR09C0028I1 (zh)	2009-09-25
AR011217A1 (es)	2000-08-02
DE122009000033I1 (de)	2009-09-17
KR20010006233A (ko)	2001-01-26
SK139699A3 (en)	2000-11-07
TR199902956T2 (xx)	2000-08-21
NZ500142A (en)	2001-10-26
TW505658B (en)	2002-10-11
HUP0002704A2 (hu)	2000-12-28
AU6969898A (en)	1998-11-11
US6214798B1 (en)	2001-04-10
CY2009008I2 (el)	2012-01-25
CZ299097B6 (cs)	2008-04-23
JP2001523229A (ja)	2001-11-20
PT1003774E (pt)	2006-05-31
ATE319736T1 (de)	2006-03-15
HU224836B1 (en)	2006-03-28
CN1230442C (zh)	2005-12-07
EE9900479A (et)	2000-06-15
WO1998046634A1 (en)	1998-10-22
NL300395I1 (nl)	2009-09-01
SI1003774T1 (sl)	2006-08-31
ES2260833T3 (es)	2006-11-01
SK285381B6 (sk)	2006-12-07
NO2009016I2 (no)	2014-08-25
CA2286190C (en)	2007-01-09
EP1003774A1 (en)	2000-05-31
DE69833751T2 (de)	2006-11-09
ZA983062B (en)	1998-10-20
JP2005120101A (ja)	2005-05-12
PL194509B1 (pl)	2007-06-29
UY24958A1 (es)	2001-03-16
AU728642B2 (en)	2001-01-11
LU91585I2 (fr)	2009-09-17
CN1259959A (zh)	2000-07-12
DE69833751D1 (de)	2006-05-04
JP3645255B1 (ja)	2005-05-11
HRP980197B1 (en)	2002-08-31
HRP980197A2 (en)	1999-02-28
HK1025104A1 (en)	2000-11-03
DE122009000033I2 (de)	2011-07-21
US5925730A (en)	1999-07-20
HUP0002704A3 (en)	2003-08-28
NO994906L (no)	1999-12-13
EE03974B1 (et)	2003-02-17
PL336213A1 (en)	2000-06-05
CY1108063T1 (el)	2012-01-25
NL300395I2 (nl)	2010-01-04
CA2286190A1 (en)	1998-10-22
RU2199549C2 (ru)	2003-02-27
KR100519421B1 (ko)	2005-10-06
CZ358699A3 (cs)	2000-06-14
CY2009008I1 (el)	2012-01-25
JP4249806B2 (ja)	2009-04-08
NO994906D0 (no)	1999-10-08
UA58547C2 (uk)	2003-08-15

Publication	Publication Date	Title
NO324991B1 (no)	2008-01-14	GnRH antagonistpeptid samt farmasoytisk preparat inneholdende det samme.
EP0973801B1 (en)	2002-12-18	GnRH ANTAGONISTS
EP0500695B1 (en)	1998-02-25	GnRH ANALOGS
US6747125B1 (en)	2004-06-08	Peptide intermediates for making GnRH antagonists
HU217552B (hu)	2000-02-28	GnRH-antagonista peptidek
HU215855B (hu)	2001-02-28	Eljárás LH-RH-analógok és ilyen hatóanyagot tartalmazó gyógyászati készítmények előállítására
EP0201260A2 (en)	1986-11-12	GnRH antagonists
EP0575490B1 (en)	1999-08-04	GnRH ANALOGS
HU190949B (en)	1986-12-28	Process for producing peptides antagonistic with hormones for releasing gonadotropine
AU633384C (en)	1994-02-17	GnRH analogs

Legal Events

Date	Code	Title	Description
2009-09-07	CREP	Change of representative	Representative=s name: OSLO PATENTKONTOR AS, POSTBOKS 7007 MAJORSTUA, 030
2014-08-25	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: DEGARELIX EVENTUELT I FORM AV ET FARMASOYTISK AKSEPTABELT SALT SA SOM ACETATET; REG. NO/DATE: EU108504001 20090217 Spc suppl protection certif: 2009016 Filing date: 20090723 Extension date: 20230413
2018-05-07	MK1K	Patent expired
2023-05-15	SPCX	Expiry of an spc	Spc suppl protection certif: 2009016 Expiry date: 20230504